Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 3/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 4/20 | 0.31 |
| ▸ | MAOB | P27338 | 4/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | HPD | P32754 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22016240 | 0.87 | GRM4 (0.43) | ADORA3ADORA2AADORA1KDM5AGRM4 | |
| SCHEMBL4547801 | 0.87 | KDM5A (0.41) | ADORA3ADORA2AADORA1KDM5AFEN1 | |
| SCHEMBL22016239 | 0.78 | ADORA3 (0.43) | ADORA3ADORA2AADORA1KDM5AGRM4 | |
| SCHEMBL4547798 | 0.75 | ERCC1 (0.44) | FEN1 | |
| SCHEMBL12049021 | 0.75 | HPD (0.42) | ADORA3ADORA2AADORA1KDM5AGRM4 | |
| SCHEMBL21420952 | 0.72 | MAOA (0.54) | MAOAMAOBACHECYP2D6 | |
| SCHEMBL22017503 | 0.71 | FEN1 (0.60) | ADORA3ADORA2AADORA1FEN1HTR6 | |
| SCHEMBL9534299 | 0.70 | ADORA3 (0.49) | ADORA3ADORA2AADORA1GRM4FEN1 | |
| SCHEMBL4547804 | 0.70 | GRM4 (0.34) | GRM4 | |
| SCHEMBL21676746 | 0.69 | MAOA (0.39) | ADORA3ADORA2AADORA1KDM5AGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501749-B2 | Azaquinazolinediones chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| US-20120108597-A1 | Azaquinazolinediones Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108597-A1 | Azaquinazolinediones Chymase Inhibitors | CMA1, SERPINB1, CTSC | ADORA3 4114/4885ADORA2A 4651/4885ADORA1 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.